PEACE-1: prognostic biomarkers in de novo metastatic prostate cancer

ARCHES: OS by high or low disease volume and progression to mHSPC or de novo mHSPC

Genomic characterization of patients with de-novo high-volume mCSPC compared to those without

Can circulating tumour DNA guide treatment intensification in de novo metastatic prostate cancer?

Debulking & Metastatic #ProstateCancer | #MarkScholzMD #AlexScholz #PCRI

Enzalutamide + ADT in Men with De Novo mHSPC: The ARCHES Trial

Metastatic #ProstateCancer Treatment Case Study | #MarkScholzMD #AlexScholz #PCRI

Triplet Therapy for Metastatic Hormone-sensitive Prostate Cancer

Untreated Metastatic Prostate Cancer - 2021 Prostate Cancer Patient Conference

Stories of Advanced Prostate Cancer Remissions | Ask a Prostate Cancer Expert, Mark Scholz, MD

PROSTATE CANCER: LIFE EXPECTANCY AFTER DIAGNOSIS

Systemic triple therapy in metastatic hormone-sensitive prostate cancer

Bone Metastasis: Diagnosis and Scans | #MarkScholzMD #AlexScholz #PCRI

Oligo-metastatic Prostate Cancer

Early Treatment Intensification for mCSPC: Optimising Patient Selection and Treatment

Quality of life in treatment of metastatic prostate cancer patients

What Are Advanced Prostate Cancer Treatment Options?

Triplet Therapy vs. ADT: Choosing the Right Approach for Metastatic Prostate Cancer

Prostate Cancer Prognosis and Life Expectancy for Bone Metastases

Newly Diagnosed Metastatic Prostate Cancer Treatment